These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880 [TBL] [Abstract][Full Text] [Related]
3. A survey of the clinical experience with dermatan sulfate. Gianese F; Lucchelli PE Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090 [No Abstract] [Full Text] [Related]
4. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion. Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic profile of sulfamino-galactosaminoglycans. Pescador R; Porta R; Mantovani M; Prino G; Casu B; Naggi A; Torri G; Walenga JM; Hoppensteadt DA; Fareed J Semin Thromb Hemost; 1991; 17 Suppl 1():74-9. PubMed ID: 1906197 [No Abstract] [Full Text] [Related]
7. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate. Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256 [TBL] [Abstract][Full Text] [Related]
8. Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Saivin S; Dol F; Caranobe C; Petitou M; Lormeau JC; Sie P; Houin G; Boneu B Thromb Res; 1992 Jun; 66(5):527-35. PubMed ID: 1523609 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of dermatan sulfate and oversulfated dermatan sulfate in plasma by high-performance liquid chromatography with postcolumn fluorescence derivatization. Huang Y; Washio Y; Hara M; Toyoda H; Koshiishi I; Toida T; Imanari T Anal Biochem; 1996 Sep; 240(2):227-34. PubMed ID: 8811915 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection. Dol F; Houin G; Dupouy D; Cadroy Y; Caranobe C; Gabaig AM; Mardiguian J; Sié P; Boneu B Thromb Haemost; 1988 Apr; 59(2):255-8. PubMed ID: 3388296 [TBL] [Abstract][Full Text] [Related]
12. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate. Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168 [No Abstract] [Full Text] [Related]
14. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin. Kaiser B; Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate. Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760 [TBL] [Abstract][Full Text] [Related]
16. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein. Calabrese GC; Alberto MF; Tubio R; Marani MM; Fernández De Recondo ME; Lazzari M; Recondo EF Thromb Res; 2004; 113(3-4):243-50. PubMed ID: 15140589 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of dermatan sulfate after intravenous and intramuscular administration to healthy volunteers. Blardi P; Messa GL; Urso R; Di Perri T Int J Clin Pharmacol Res; 1993; 13(4):231-8. PubMed ID: 8150550 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material. Dawes J Thromb Haemost; 1993 Apr; 69(4):339-43. PubMed ID: 8497846 [TBL] [Abstract][Full Text] [Related]
19. Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week. Dettori AG; Zamboni V; Manotti C; Canova N; Barbanti M; Palazzini E Thromb Res; 1996 Jul; 83(1):103-9. PubMed ID: 8837309 [No Abstract] [Full Text] [Related]
20. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Bendayan P; Boccalon H; Dupouy D; Boneu B Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]